Protuoso Biosciences Raises $9.5M Seed for Multifunctional Biologics

Fundraise Insider tracks newly funded startups each week and delivers verified C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Protuoso Biosciences has closed an oversubscribed $9.5 million Seed round led by Taya Venture and Darwin Ventures, with participation from NSG Ventures, SEEDS, and other investors.

The company is developing multifunctional biologics to address complex diseases with high unmet need. At the core of its platform are MUXBODIES, fully recombinant fusion proteins that integrate multiple modalities to engage a combination of disease mechanisms.

Proceeds will go toward advancing the company’s multifunctional protein engineering platform and its broad pipeline across cardiometabolic, oncology, and autoimmune diseases.

Protuoso is building a therapeutic-agnostic hub-and-spoke model. Its core protein engineering platform acts as the central hub to generate multiple differentiated therapeutic assets across disease areas of high unmet need, and programs are then advanced through focused spokes. That structure enables parallel development and early business development engagement at the asset level.

The platform combines computational protein design, massively parallel synthetic biology, and AI-enabled modular protein engineering to optimize these multi-domain fusion proteins.